Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction on Monday, November 16th. The stock was sold at an average price of $98.38, for a total value of $1,967,600.00. Following the completion of the transaction, the chief executive officer owned 767,780 shares of the company’s stock, valued at $75,534,196.40. This represents a 2.54% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Helen Torley also recently made the following trade(s):
- On Friday, November 13th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $100.38, for a total value of $2,007,600.00.
- On Tuesday, October 6th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $109.58, for a total value of $2,191,600.00.
- On Thursday, October 8th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $109.40, for a total value of $2,188,000.00.
- On Wednesday, September 9th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $107.43, for a total value of $2,148,600.00.
- On Friday, September 11th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $107.24, for a total value of $2,144,800.00.
- On Tuesday, August 18th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $104.18, for a total transaction of $2,083,600.00.
Halozyme Therapeutics Price Performance
HALO opened at $96.50 on Tuesday. The company has a debt-to-equity ratio of 13.50, a quick ratio of 3.60 and a current ratio of 3.88. The stock has a market capitalization of $11.00 billion, a P/E ratio of 18.07, a P/E/G ratio of 0.38 and a beta of 0.92. The company’s 50-day simple moving average is $114.29 and its two-hundred day simple moving average is $85.63. Halozyme Therapeutics, Inc. has a 52-week low of $61.22 and a 52-week high of $134.00.
Institutional Investors Weigh In On Halozyme Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in HALO. Hilton Head Capital Partners LLC bought a new position in shares of Halozyme Therapeutics in the 3rd quarter worth approximately $33,000. CoreCap Advisors LLC boosted its holdings in shares of Halozyme Therapeutics by 98.0% in the third quarter. CoreCap Advisors LLC now owns 303 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 150 shares during the last quarter. MidFirst Bank bought a new stake in Halozyme Therapeutics during the second quarter valued at approximately $27,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in Halozyme Therapeutics during the second quarter valued at approximately $28,000. Finally, Quantbot Technologies LP bought a new stake in Halozyme Therapeutics during the second quarter valued at approximately $30,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.
Analyst Upgrades and Downgrades
Several brokerages recently issued reports on HALO. TD Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a report on Monday. Citigroup reiterated a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Friday, August 7th. JPMorgan Chase & Co. increased their price target on Halozyme Therapeutics from $78.00 to $79.00 and gave the company a “neutral” rating in a report on Tuesday, November 3rd. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Finally, Zacks Research downgraded Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 11th. Seven analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $108.18.
View Our Latest Research Report on HALO
About Halozyme Therapeutics
Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion. Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.
Featured Stories
- Five stocks we like better than Halozyme Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
